רווח למניה בשנים עשר החודשים האחרונים: TScan Therapeutics Inc (TCRX)

TScan Therapeutics (TCRX) maintains its position thanks to T-Scan platform innovations in solid tumor therapy. The annual earnings per share trend on the GURU.Markets chart demonstrates that -0.91 represents the current metric level. The business relies on a closed scientific circuit with licenses for pharma behemoths, overcoming the challenges of costly production and strict regulatory oversight in the oncology sector.

Earnings per share (EPS TTM) determines the portion of total income allocated to a single security over a year. This metric is calculated by dividing net profit by the number of shares outstanding. By analyzing the trend of net income per share, an investor identifies the efficiency of capital management. For TScan Therapeutics (TCRX), this indicator reflects the cost of investments in T-cell therapy. High expenditures on expert teams and target discovery directly impact the final value of this metric.